Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.31 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266351 | 0.81 | KCNH2 (0.55) | KCNH2CYP19A1MAPTSMN1; SMN2CYSLTR2 | |
| SCHEMBL10388208 | 0.76 | KCNH2 (0.49) | KCNH2MAPTSMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL7205558 | 0.71 | KCNH2 (0.35) | KCNH2MAPTSMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL5757659 | 0.71 | — | — | |
| SCHEMBL2104797 | 0.71 | ACACB (0.46) | KCNH2CYP2C9CYP2C19CYP2D6MAPT | |
| SCHEMBL21899164 | 0.70 | KCNA3 (0.50) | KCNH2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL5759296 | 0.69 | SMN1; SMN2 (0.36) | CYP2C9CYP2C19MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL864159 | 0.69 | KDM4E (0.58) | KCNH2CYP2C9CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL7207747 | 0.69 | KCNH2 (0.36) | KCNH2MAPTSMN1; SMN2HSD17B10CYSLTR2 | |
| SCHEMBL22266229 | 0.69 | KCNA3 (0.48) | KCNH2CYP2C9CYP2C19CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | claimed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | KCNH2 3773/4885CYP2C9 2153/4885CYP2C19 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.